<DOC>
	<DOCNO>NCT00476060</DOCNO>
	<brief_summary>The standard treatment decompensated cirrhosis liver transplantation , however , several limitation . Recent animal study suggest bone marrow stem cell transplantation lead regression liver fibrosis . The investigator already complete phase 1 study bone marrow mesenchymal stem cell ( MSC ) transplantation 4 patient cirrhosis . The procedure safe , feasible , lead somewhat promising result ( Mohamadnejad M , et al . 2006 ; Submitted publication ) . The aim study find efficacy new treatment strategy set multicenter , randomize placebo-controlled trial 50 patient decompensated cirrhosis .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Transplantation Decompensated Cirrhosis</brief_title>
	<detailed_description>The standard treatment decompensated cirrhosis liver transplantation , however , several limitation , include small donor pool , long wait list , several complication . Recent animal study suggest bone marrow stem cell transplantation lead regression liver fibrosis . The investigator already complete phase 1 study bone marrow mesenchymal stem cell ( MSC ) transplantation 4 patient cirrhosis . The procedure safe , feasible , lead somewhat promising result ( Mohamadnejad M , et al . 2006 ; Submitted publication ) . The aim study find efficacy new treatment strategy set multicenter , randomize placebo control trial . After assignment write informed consent , thirty six patient decompensated cirrhosis enrol , randomize block randomization treatment placebo arm . All enrol patient wait list liver transplantation . In treatment arm bone marrow patient aspirate , autologous bone marrow mesenchymal stem cell culture , infused peripheral vein . Also , correspond placebo infuse placebo group . The patient follow 1 year performing procedure .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>Cirrhosis ( diagnosed clinical , biochemical , sonographic , histologic evidence cirrhosis ) ( Patients histological documentation cirrhosis enrollment . However , evidence severe coagulopathy liver biopsy may perform ) Evidences decompensated liver disease screening ( e.g . child class B , C ) Presence active hepatic encephalopathy Refractory ascites Evidences active autoimmune liver disease ( e.g . gamma globulin 2 time upper limit normal , ALT &gt; 3 time normal patient autoimmune hepatitis ) Hepatocellular carcinoma malignancy Active infectious disease Presences severe underlie cardiac , pulmonary , renal disease Alcohol use last 3 month screen Use hepatotoxic drug last 3 month screen Unwilling assign inform consent Presence significant extrahepatic biliary disease ( e.g . CBD stone , PSC , etc . ) Positive HIV ab Positive HBsAg detectable HBV DNA PCR Positive HCV Ab detectable HCV RNA PCR Active thrombosis portal hepatic vein Serum Cr &gt; 1.8 mg/dL screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Cirrhosis</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>MELD score</keyword>
	<keyword>Quality life</keyword>
</DOC>